DOCSLIB.ORG

Read PDF Edition

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Read PDF Edition 30 30 REVIEW OF OPTOMETRY Managing Traumatic Hyphema, p. 18 • Recognizing Pseudotumor Cerebri, p. 79 29 29 28 28 27 27 ■ VOL. 155 NO. 7 July 15, 2018 www.reviewofoptometry.com 26 26 24TH ANNUAL GLAUCOMA REPORT ■ JULY 15, 2018 25 25 24 24 ■ ANNUAL GLAUCOMA REPORT 23 23 22 22 21 21 ■ MEDICATIONS 20 20 ■ LASERS 19 19 ■ MIGS 18 18 ■ SURGERY 17 17 ■ NUTRITION 16 The most comprehensive list ever assembled. Your guide to meds, MIGS and more. 16 Begins page 23. 15 15 001_ro0718_fc2.indd 1 7/5/18 5:15 PM INTRODUCING REFRESH® REPAIR The fi rst and only artifi cial tear in the U.S. formulated with CMC, HA,* and Osmoprotectants. REFRESH® REPAIR helps promote healing of the cornea and conjunctival epithelia and improves visual performance in Dry Eye patients. Safe to use with contacts. refreshbrand.com/doc | *HA is an inactive ingredient. © 2018 Allergan. All rights reserved. All trademarks are the property of their respective owners. REF115212 05/18 RO0618_Allergan Refresh.indd 1 5/31/18 2:55 PM Earn up to 2018 MEETINGS 12 CE Credits* MEETING CO-CHAIRS: MURRAY FINGERET, OD ROBERT N. WEINREB, MD CE CONFERENCES 10th Annual EAST COAST OPTOMETRIC GLAUCOMA SYMPOSIUM September 21-22, 2018 Rittenhouse Hotel 210 W. Rittenhouse Square PHILADELPHIA, PA For up-to-date information please visit: www.reviewscecom/ECOGS2018 Please call the hotel directly at 215-546-9000 and identify yourself as a participant of the East Coast Optometric Glaucoma Symposium. 10th Annual WEST COAST OPTOMETRIC GLAUCOMA SYMPOSIUM December 14-15, 2018 Monarch Hotel 1 Monarch DANA POINT, CA For up-to-date information please visit: www.reviewsce.com/WCOGS2018 Please call the hotel directly at 800-722-1543 and identify yourself as a participant of the West Coast Optometric Glaucoma Symposium. Administered by Review Group Vision Care Education, LLC *Approval pending For up-to-date information, go to www.reviewsce.com/events call 877-451-6514 or e-mail [email protected] Review Group Vision Care Education, LLC partners with Salus University for those ODs who are licensed in states that require university credit. News Review VOL. 155 NO. 7 ■ JULY 15, 2018 IN THE NEWS New Hypertension A new study suggests the neural circuit mechanisms underlying recovery of Guidelines: Now What? eye dominance and acuity operate independently, potentially turning cur- Research suggests some screening changes that may rent amblyopia treatment on its head. The study evaluated the visual acuity of impact your care. mice for whom the ngr1 gene had been By Bill Kekevian, Senior Editor removed; the results show that, even for mice whose eye dominance remained ike diabetes, hypertension Glaucoma specialist James Fanel- impaired, visual acuity could still improve. rates in the United States and li, OD, says this research further Stephany C, Ma X, Dorton H, et al. Distinct circuits worldwide have exploded. supports the idea that optometrists for recovery of eye dominance and acuity in murine L amblyopia. Current Biology. June 7, 2018. [Epub ahead In fact, researchers estimate that “should consider systemic blood of print]. 1.3 billion people worldwide pressure a modifi able risk factor for State Senator Ed Hernandez, OD, of suffer from it.1 For most primary both glaucoma development and West Covina, Calif., recently won care physicians, this is fairly easily glaucoma progression.” the Democratic Party’s nomination handled by encouraging the patient But it isn’t a simple see-saw effect for California’s Lieutenant Governor to make lifestyle changes to control in which one goes up, causing the seat.1 He’s earned the endorsement of their blood pressure (BP), as well other to go down. One of the major several local eye care practices and as prescribing BP-lowering medica- fi ndings of the research shows that California optometrists. His website tions. But, for eye care clinicians, “extreme falls in nighttime—but boasts various health care related lowering BP can have a dangerous not daytime—systolic and diastolic goals and policies, such as champion- side effect: elevated risk for glauco- blood pressure were signifi cantly as- ing lower drug prices and passing ma. Although it is weak, research- sociated with a higher prevalence of clean water and air regulations.2 ers point to a signifi cant positive glaucomatous optic neuropathy.” 1. Thompson J. California Optometric Association ap- relationship between systemic Dr. Fanelli adds that patients plauds Dr. Ed Hernandez’s election night victory. www. coavision.org/fi les/Ed%20Hernandez%20Primary%20 blood pressure and intraocular should avoid taking BP medications Statement%20FINAL.pdf. June 6, 2018. Accessed pressure (IOP). “The relationship at night, as a nocturnal drop in BP June 7, 2018. 2. Dr. Ed Hernandez for Lt. Governor 2018. www.edher- between glaucoma and systemic hy- is often when IOP tends to increase. nandez4ca.com/media. Accessed June 7, 2018. pertension is multifaceted and often Due to the nuanced nature of BP Researchers recently used binocular puzzling,” reads a report, published and IOP, the authors recommend a optical coherence tomography (OCT) in the Journal of Glaucoma.2 close partnership between eye care to measure the size of strabismus, Part of that puzzle involves and primary care for those strad- with positive results. In evaluating 15 discovering precisely what that re- dling hypertension and glaucoma. patients with strabismus and 15 controls lationship is. The authors relied on “ODs don’t interact with internal with both anterior segment OCT and population-based studies, prospec- medicine and family practice and alternating prism cover test (APCT), tive longitudinal studies and ran- the medical community as a whole they found OCT correctly identifi ed the domized clinical trials to organize enough,” Dr. Fanelli adds. “We type and direction of the deviation in all “evidence that lower systemic BP need to comanage and take an ac- 15 patients with strabismus. Imaging and lower ocular perfusion pressure tive role. It needs to be done all the was strongly correlated with the APCT are associated with greater glau- time.” measurement as well. coma prevalence and a higher rate 1. Bloch MJ. Worldwide prevalence of hypertension exceeds of glaucoma progression.” How- 1.3 billion. J American Society of Hypertension: JASH. Chopra R, Mulholland PJ, Tailor VK, et al. Use of a 2016;10(10):753-4. binocular optical coherence tomography system to evaluate strabismus in primary position. JAMA Ophthal- ever, they are careful not to imply 2. De Moraes C, Cioffi G, Weinreb R, Liebmann J. Perspective: mol. May 31, 2018. [Epub ahead of print]. new recommendations for the treatment of systemic hyperten- that treating systemic hypertension sion and their potential implications for glaucoma management. increases the risk of glaucoma. J Glaucoma. May 10, 2018. [Epub ahead of print]. 4 REVIEW OF OPTOMETRY JULY 15, 2018 0004_ro0718_news.indd04_ro0718_news.indd 4 77/5/18/5/18 111:231:23 AAMM 100% PRESERVATIVE-FREE ORDER FREE SAMPLES Go to either website and select “Request Sample” www.Zioptan.com www.CosoptPF.com Cosopt is a registered trademark of Merck Sharp & Dohme Corp and is used under license. ZIOPTAN is a registered trademark of Merck Sharp & Dohme Corp and is used under license. ZIOPTAN is licensed by Santen Pharmaceutical Co., Ltd. ©2017 Akorn, Inc. All rights reserved. P481(a) Rev 4/17 RP0118_Akon Zioptan.indd 1 12/19/17 2:42 PM News Review OCT-A Not Always Better than OCT lthough the diagnostic value viduals. The researchers measured densities,” the study said. of optical coherence tomog- “retinal thickness and retinal vessel “OCT measurement of inner Araphy angiography (OCT-A) density over the 3x3mm2 macula macular thickness shows a higher compared with conventional OCT using swept-source OCT (SS-OCT) diagnostic performance to detect measurement in glaucoma remains and OCT-A, respectively. They glaucoma and a stronger structure- inconclusive, many researchers and found the inner macular vessel den- function association than the cur- clinicians fall into the trap of as- sity was 4.3% smaller in eyes with rently used OCT-A measurement of suming that newer is always better. glaucoma compared with healthy inner macular vessel density,” the However, researchers in Hong eyes. Inner macular vessel thick- study authors conclude. Kong took a closer look at both ness was also smaller by 21.1µm, “These fi ndings may suggest that modalities and found OCT-A has compared with healthy eyes. OCT-A of the macula has a limited its limitations, leading them to When comparing the two mea- role in the diagnostic evaluation of believe conventional OCT remains surements, they found that “at 90% glaucoma.” a better option when viewing the specifi city, the sensitivity of mean macula in some cases. inner macular thicknesses for detec- Wan KH, Lam AKN, Leung CK. Optical coherence tomography angiography compared with optical coherence tomography The study includes 115 patients tion of glaucoma was greater than macular measurements for detection of glaucoma. JAMA with glaucoma and 35 healthy indi- that of mean inner macular vessel Ophthalmol. May 31, 2018. [Epub ahead of print]. “Tele-optometry” Offers Remote Exams new telemedicine company perform a prescreening exam, offi ces, which would allow home- says it can help optometrists including autorefraction, tonometry, bound licensed optometrists the Aperform virtual eye exams. fundus photography, a video slit- chance to return to their profession. Touting this concept as “tele- lamp and auto-lensmeter readings. Now optometrists “can expand optometry,” DigitalOptometrics The information would then be their practices by opening addition- hopes to provide convenience to sent to a licensed optometrist who al locations and can, in fact, be in patients seeking exams and greater would check the visual fi ndings two to three places at the same time opportunities for ODs—without the and discusses them with the patient by seeing some of their patients in acrimony that typically surrounds through a live videoconference.
Load more

Recommended publications
  • 202514Orig1s000
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 202514Orig1s000 CLINICAL PHARMACOLOGY AND BIOPHARMACEUTICS REVIEW(S) OFFICE OF CLINICAL PHARMACOLOGY REVIEW NDA: 202-514 Submission Date(s): January 7, 2011 Proposed Brand Name TBD Generic Name Tafluprost Primary Reviewer Yongheng Zhang, Ph.D. Team Leader Philip M. Colangelo, Pharm.D., Ph.D. OCP Division DCP4 OND Division DTOP Applicant MERCK & CO., Inc. Relevant IND(s) 062690 Submission Type; Code 1S(NME) Formulation; Strength(s) Tafluprost 0.0015% Ophthalmic Solution Indication For the reduction of elevated intraocular pressure in open-angle glaucoma or ocular hypertension Dosage and Administration One drop of Tafluprost 0.0015% ophthalmic solution in the conjunctival sac of the affected eye(s) once daily in the evening TABLE OF CONTENTS 1. EXECUTIVE SUMMARY .................................................................................................................. 2 1.1. RECOMMENDATION ....................................................................................................................... 3 1.2. PHASE IV COMMITMENTS............................................................................................................. 3 1.3. SUMMARY OF IMPORTANT CLINICAL PHARMACOLOGY AND BIOPHARMACEUTICS FINDINGS.. 3 2. QUESTION BASED REVIEW ...........................................................................................................4 2.1. GENERAL ATTRIBUTES OF THE DRUG .........................................................................................
    [Show full text]
  • Eyelash Growth Induced by Topical Prostaglandin Analogues, Bimatoprost, Tafluprost, Travoprost, and Latanoprost in Rabbits
    JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS ORIGINAL ARTICLE Volume 00, Number 0, 2013 ª Mary Ann Liebert, Inc. DOI: 10.1089/jop.2013.0075 Eyelash Growth Induced by Topical Prostaglandin Analogues, Bimatoprost, Tafluprost, Travoprost, and Latanoprost in Rabbits Ama´lia Turner Giannico,1 Leandro Lima,1 Heloisa Helena Abil Russ,2 and Fabiano Montiani-Ferreira1 Abstract Purpose: Prostaglandin analogues (PGA) are ocular hypotensive agents used for the treatment of glaucoma. Hypertrichosis of the eyelashes has been reported in humans as a side effect. Eyelash growth was investigated with clinical trials in people using bimatoprost. Scattered reports of eyelash growth during the treatment of glaucoma with other PGA are also found in the literature. We investigated the effect of 4 different topical PGA on eyelash length. Methods: Forty New Zealand white rabbits were divided into 4 groups and received daily topical application of bimatoprost, tafluprost, travoprost, and latanoprost in the left eye for 4 weeks. The right eye received no treatment. Eyelash length was measured in both eyes before and after treatment using a stainless steel digital caliper. Results: Bimatoprost and tafluprost groups had significant increases in eyelash length. We did not observe significant eyelash growth in rabbits receiving travoprost and latanoprost after 1 month of treatment. Conclusions: Today, only bimatoprost is approved for growing eyelashes, and our research shows that ta- fluprost could be further explored by the cosmetic and pharmaceutical industry. Additional research using travoprost and latanoprost as agents for eyelash growth should be performed in the future using prolonged treatment periods to determinate whether or not these PGA induce eyelash growth, and investigate other possible side effects.
    [Show full text]
  • Optum Essential Health Benefits Enhanced Formulary PDL January
    PENICILLINS ketorolac tromethamineQL GENERIC mefenamic acid amoxicillin/clavulanate potassium nabumetone amoxicillin/clavulanate potassium ER naproxen January 2016 ampicillin naproxen sodium ampicillin sodium naproxen sodium CR ESSENTIAL HEALTH BENEFITS ampicillin-sulbactam naproxen sodium ER ENHANCED PREFERRED DRUG LIST nafcillin sodium naproxen DR The Optum Preferred Drug List is a guide identifying oxacillin sodium oxaprozin preferred brand-name medicines within select penicillin G potassium piroxicam therapeutic categories. The Preferred Drug List may piperacillin sodium/ tazobactam sulindac not include all drugs covered by your prescription sodium tolmetin sodium drug benefit. Generic medicines are available within many of the therapeutic categories listed, in addition piperacillin sodium/tazobactam Fenoprofen Calcium sodium to categories not listed, and should be considered Meclofenamate Sodium piperacillin/tazobactam as the first line of prescribing. Tolmetin Sodium Amoxicillin/Clavulanate Potassium LOW COST GENERIC PREFERRED For benefit coverage or restrictions please check indomethacin your benefit plan document(s). This listing is revised Augmentin meloxicam periodically as new drugs and new prescribing LOW COST GENERIC naproxen kit information becomes available. It is recommended amoxicillin that you bring this list of medications when you or a dicloxacillin sodium CARDIOVASCULAR covered family member sees a physician or other penicillin v potassium ACE-INHIBITORS healthcare provider. GENERIC QUINOLONES captopril ANTI-INFECTIVES
    [Show full text]
  • Two Phase 3 Clinical Trials Comparing the Safety and Efficacy of Netarsudil to Timolol in Patients with Elevated Intraocular
    Two Phase 3 Clinical Trials Comparing the Safety and Efficacy of Netarsudil to Timolol in Patients With Elevated Intraocular Pressure: Rho Kinase Elevated IOP Treatment Trial 1 and 2 (ROCKET-1 and ROCKET-2) JANET B. SERLE, L. JAY KATZ, EUGENE MCLAURIN, THERESA HEAH, NANCY RAMIREZ-DAVIS, DALE W. USNER, GARY D. NOVACK, AND CASEY C. KOPCZYNSKI, FOR THE ROCKET-1 AND ROCKET-2 STUDY GROUPS PURPOSE: To evaluate the efficacy and ocular and sys- ROCKET-2) for timolol (P < .0001 for netarsudil vs temic safety of netarsudil 0.02% ophthalmic solution, a timolol). rho-kinase inhibitor and norepinephrine transporter in- CONCLUSIONS: In 2 large, randomized, double-masked hibitor, in patients with open-angle glaucoma and ocular trials reported here, once-daily dosing of netarsudil hypertension. 0.02% was found to be effective and well tolerated for DESIGN: Double-masked, randomized noninferiority the treatment of patients with ocular hypertension and clinical trials: Rho Kinase Elevated IOP Treatment Trial open-angle glaucoma. The novel pharmacology and 1 and 2 (ROCKET-1 and ROCKET-2). aqueous humor dynamic effects of this molecule suggest METHODS: After a washout of all pre-study ocular hy- it may be a useful addition to the armamentarium of potensive medications, eligible patients were randomized ocular hypotensive medications. (Am J Ophthalmol to receive netarsudil 0.02% once daily (q.d.), timolol 2018;186:116–127. Ó 2017 The Authors. Published 0.5% twice a day (b.i.d.), and (ROCKET-2 only) netar- by Elsevier Inc. This is an open access article under the sudil 0.02% b.i.d.
    [Show full text]
  • Table 1. Glaucoma Medications: Mechanisms, Dosing and Precautions Brand Generic Mechanism of Action Dosage/Avg
    OPTOMETRIC STUDY CENTER Table 1. Glaucoma Medications: Mechanisms, Dosing and Precautions Brand Generic Mechanism of Action Dosage/Avg. % Product Sizes Side Effects Warnings Reduction CHOLINERGIC AGENTS Direct Pilocarpine (generic) Pilocarpine 1%, 2%, 4% Increases trabecular outflow BID-QID/15-25% 15ml Headache, blurred vision, myopia, retinal detachment, bronchiole constriction, Angle closure, shortness of breath, retinal narrowing of angle detachment Indirect Phospholine Iodide (Pfizer) Echothiophate iodide 0.125% Increases trabecular outflow QD-BID/15-25% 5ml Same as above plus cataractogenic iris cysts in children, pupillary block, Same as above, plus avoid prior to any increased paralysis with succinylcholine general anesthetic procedure ALPHA-2 AGONISTS Alphagan P (Allergan) Brimonidine tartrate 0.1%, 0.15% with Purite Decreases aqueous production, increases BID-TID/up to 26% 5ml, 10ml, 15ml Dry mouth, hypotension, bradycardia, follicular conjunctivitis, ocular irritation, Monitor for shortness of breath, dizziness, preservative uveoscleral outflow pruritus, dermatitis, conjunctival blanching, eyelid retraction, mydriasis, drug ocular redness and itching, fatigue allergy Brimonidine tartrate Brimonidine tartrate 0.15%, 0.2% Same as above Same as above 5ml, 10ml Same as above Same as above (generic) Iopidine (Novartis) Apraclonidine 0.5% Decreases aqueous production BID-TID/up to 25% 5ml, 10ml Same as above but higher drug allergy (40%) Same as above BETA-BLOCKERS Non-selective Betagan (Allergan) Levobunolol 0.25%, 0.5% Decreases
    [Show full text]
  • Rhopressa™ Netarsudil Ophthalmic Solution 0.02%
    Rhopressa™ Netarsudil ophthalmic solution 0.02% CDER Dermatologic and Ophthalmic Drugs Advisory Committee October 13, 2017 Aerie Pharmaceuticals, Inc. 1 Introduction Marvin Garrett Vice President, Regulatory Affairs and Quality Assurance Aerie Pharmaceuticals, Inc. 2 Aerie Pharmaceuticals • 2005: Aerie founded as a spin-out from Duke University: – Dr. Eric Toone – Dr. Casey Kopczynski – Dr. David Epstein – Dr. Epstein’s goal from the beginning: Develop a therapy that targeted the diseased tissue in glaucoma, the trabecular outflow pathway • 2006: Aerie discovered its first Rho kinase inhibitor • 2009: Aerie invented netarsudil • 2012: Netarsudil 1st clinical study • 2017: NDA filed 3 Netarsudil: A New Drug Class for Lowering IOP We are requesting a recommendation for approval of netarsudil ophthalmic solution 0.02% for reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension given one drop QD 4 Agenda Unmet Medical Needs Richard A. Lewis, MD Chief Medical Officer Aerie Pharmaceuticals, Inc. Past President, American Glaucoma Society Program Design and Efficacy Casey Kopczynski, PhD Chief Scientific Officer Aerie Pharmaceuticals, Inc. Safety Theresa Heah, MD, MBA VP Clinical Research and Medical Affairs Aerie Pharmaceuticals, Inc. Benefits and Risks Janet Serle, MD Professor of Ophthalmology Glaucoma Fellowship Director Icahn School of Medicine at Mount Sinai 5 List of Expert Responders • Cynthia Mattox, MD – Associate Professor of Ophthalmology, Tufts University School of Medicine – Current President, American Glaucoma Society • Mark Reasor, PhD – Professor of Physiology & Pharmacology, Robert C. Byrd Health Sciences Center, West Virginia University • Bennie H. Jeng, MD – Professor and Chair, Department of Ophthalmology & Visual Sciences, University of Maryland School of Medicine • Dale Usner, PhD – Biostatistics Consultant to Aerie Pharmaceuticals, Inc.
    [Show full text]
  • Looking for New Classes of Bronchodilators
    REVIEW BRONCHODILATORS The future of bronchodilation: looking for new classes of bronchodilators Mario Cazzola1, Paola Rogliani 1 and Maria Gabriella Matera2 Affiliations: 1Dept of Experimental Medicine, University of Rome Tor Vergata, Rome, Italy. 2Dept of Experimental Medicine, University of Campania “Luigi Vanvitelli”, Naples, Italy. Correspondence: Mario Cazzola, Dept of Experimental Medicine, University of Rome Tor Vergata, Via Montpellier 1, Rome, 00133, Italy. E-mail: [email protected] @ERSpublications There is a real interest among researchers and the pharmaceutical industry in developing novel bronchodilators. There are several new opportunities; however, they are mostly in a preclinical phase. They could better optimise bronchodilation. http://bit.ly/2lW1q39 Cite this article as: Cazzola M, Rogliani P, Matera MG. The future of bronchodilation: looking for new classes of bronchodilators. Eur Respir Rev 2019; 28: 190095 [https://doi.org/10.1183/16000617.0095-2019]. ABSTRACT Available bronchodilators can satisfy many of the needs of patients suffering from airway disorders, but they often do not relieve symptoms and their long-term use raises safety concerns. Therefore, there is interest in developing new classes that could help to overcome the limits that characterise the existing classes. At least nine potential new classes of bronchodilators have been identified: 1) selective phosphodiesterase inhibitors; 2) bitter-taste receptor agonists; 3) E-prostanoid receptor 4 agonists; 4) Rho kinase inhibitors; 5) calcilytics; 6) agonists of peroxisome proliferator-activated receptor-γ; 7) agonists of relaxin receptor 1; 8) soluble guanylyl cyclase activators; and 9) pepducins. They are under consideration, but they are mostly in a preclinical phase and, consequently, we still do not know which classes will actually be developed for clinical use and whether it will be proven that a possible clinical benefit outweighs the impact of any adverse effect.
    [Show full text]
  • Yellox, Bromfenac
    ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Yellox 0.9 mg/ml eye drops, solution 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One ml of solution contains 0.9 mg bromfenac (as sodium sesquihydrate). One drop contains approximately 33 micrograms bromfenac. Excipient: Each ml of solution contains 50 micrograms of benzalkonium chloride. For a full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Eye drops, solution. Clear yellow solution. pH: 8.1-8.5; osmolality: 270-330 mOsmol/kg 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Treatment of postoperative ocular inflammation following cataract extraction in adults. 4.2 Posology and method of administration Posology Use in adults, including the elderly The dose is one drop of Yellox in the affected eye(s) twice daily, beginning the next day after cataract surgery and continuing through the first 2 weeks of the postoperative period. The treatment should not exceed 2 weeks as safety data beyond this is not available. Paediatric population The safety and efficacy of bromfenac in paediatric patients has not been established. No data are available. Hepatic and renal impairment Yellox has not been studied in patients with hepatic disease or renal impairment. Method of administration For ocular use. If more than one topical ophtalmic medicinal product is being used, each one should be administered at least 5 minutes apart. To prevent contamination of the dropper-tip and solution, care must be taken not to touch the eyelids, surrounding areas or other surfaces with the dropper-tip of the bottle. Instruct patient to keep the bottle tightly closed when not in use.
    [Show full text]
  • Efficacy and Safety of the Fixed Combinations of Tafluprost/Timolol
    www.nature.com/scientificreports OPEN Efcacy and safety of the fxed combinations of tafuprost/timolol and latanoprost/carteolol Received: 4 February 2019 Masahiro Fuwa, Atsushi Shimazaki, Masafumi Mieda, Naoko Yamashita, Takahiro Akaishi, Accepted: 7 May 2019 Takazumi Taniguchi & Masatomo Kato Published: xx xx xxxx In this study, we made a comparative efcacy and safety assessment of two diferent fxed combinations of drugs, viz., tafuprost/timolol (TAF/TIM) and latanoprost/carteolol (LAT/CAR), by determining their efects on intraocular pressure (IOP) in ocular normotensive monkeys and examining their toxic efects on ocular surface using human corneal epithelial cells. TAF/TIM was found to be more efective in lowering IOP for a longer duration compared to LAT/CAR. We found that the diference in the intensity of IOP-lowering efect was because of the diferences in the strength of timolol compared with that of carteolol as a beta-adrenergic antagonist and strength of tafuprost compared with that of latanoprost as a prostaglandin analogue. In addition, TAF/TIM showed much less cytotoxic efects compared to LAT/CAR on the human corneal epithelial cells. Our fndings showed that TAF/TIM is better than LAT/CAR with regard to the IOP-lowering efect in monkeys and toxicity on ocular surface. Glaucoma is a neurodegenerative disease of the eyes characterised by selective retinal ganglion cell loss, fol- lowed by progressive defects in visual feld, resulting in the principal cause of irreversible blindness worldwide1–4. Elevated intraocular pressure (IOP) is an important contributor for the progression of glaucoma, for which the current treatment primarily involves IOP reduction1,5–8.
    [Show full text]
  • Review Article Analysis of the Responsiveness of Latanoprost, Travoprost, Bimatoprost, and Tafluprost in the Treatment of OAG/OHT Patients
    Hindawi Journal of Ophthalmology Volume 2021, Article ID 5586719, 12 pages https://doi.org/10.1155/2021/5586719 Review Article Analysis of the Responsiveness of Latanoprost, Travoprost, Bimatoprost, and Tafluprost in the Treatment of OAG/OHT Patients Ziyan Cai ,1 Mengdan Cao,1 Ke Liu,1 and Xuanchu Duan 2 1Department of Ophthalmology, e Second Xiangya Hospital of Central South University, Changsha, Hunan, China 2Department of Ophthalmology, Changsha Aier Eye Hospital, Changsha, Hunan, China Correspondence should be addressed to Xuanchu Duan; [email protected] Received 22 February 2021; Accepted 18 May 2021; Published 25 May 2021 Academic Editor: Enrique Menc´ıa-Gutie´rrez Copyright © 2021 Ziyan Cai et al. -is is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Aim. Within the clinical setting, some patients have been identified as lacking in response to PGAs. -is meta-analysis study aimed to evaluate the responsiveness of latanoprost, travoprost, bimatoprost, and tafluprost in OAG/OHT patients, latanoprost nonresponders (LNRs), and the IOP-reducing efficacy and safety. Methods. A literature search was conducted on PubMed, Embase, and the Cochrane Controlled Trials Register. -e primary clinical endpoint was the number of responders at the end of the study. -e secondary clinical endpoint was the IOP reduction at the endpoint from baseline. Safety evaluation included five common adverse events: conjunctival hyperemia, hypertrichosis, ocular burning, ocular itching, and foreign-body sensation. Results. Eleven articles containing ten RCTs were included in this meta-analysis study. -e results highlighted that, in the OAG/ OHT population, there was no statistically significant difference in the responsiveness of the four PGAs.
    [Show full text]
  • Prostaglandin Analogs for Glaucoma
    Prostaglandin Analogs Company Brand Generic Name Name Akorn Inc. Zioptan™ Tafluprost ophthalmic solution 0.0015% (PF) Allergan Inc. Durysta™ Bimatoprost 10 mcg implant Allergan Inc. Lumigan® Bimatoprost 0.01%, 0.03% Bausch & Lomb, Vyzulta™ Latanoprostene bunod 0.024% Inc. Novartis Travatan® Z Travaprost 0.004% Pfizer Inc. Xalatan® Latanoprost 0.005% Sun Ophthalmics Xelpros™ Latanoprost ophthalmic emulsion 0.005% Prostaglandin analogs work by increasing the outflow of intraocular fluid from the eye. They have few systemic side effects but are associated with changes to the eye itself, including change in iris color and growth of eyelashes. Depending on the individual, one brand of this type of medication may be more effective and produce fewer side effects. Prostaglandin analogs are taken as eye drops (except Durysta™ which is an implant). They are effective at reducing intraocular pressure in people who have open-angle glaucoma. Latanoprost and some formulations of bimatoprost and travoprost are available in generic form. Tafluprost is a preservative-free prostaglandin analog. Side Effects Side effects can include eye color change, darkening of eyelid skin, eyelash growth, droopy eyelids, sunken eyes, stinging, eye redness, and itching. Follow these steps to make it easier to put in eye drops: Preparing the Drops ● Always wash your hands before handling your eye drops or touching your eyes. ● If you’re wearing contact lenses, take them out — unless your ophthalmologist has ​ ​ told you to leave them in. ● Shake the drops vigorously before using them. ● Remove the cap of the eye drop medication. ○ Do not touch the dropper tip. Putting in Eye Drops ● Tilt your head back slightly and look up.
    [Show full text]
  • Use of Topical Bromfenac for Treating Ocular Pain and Inflammation Beyond Cataract Surgery: a Review of Published Studies
    Clinical Ophthalmology Dovepress open access to scientific and medical research Open Access Full Text Article REVIEW Use of topical bromfenac for treating ocular pain and inflammation beyond cataract surgery: a review of published studies This article was published in the following Dove Press journal: Clinical Ophthalmology Barry A Schechter Abstract: Topical ophthalmic nonsteroidal anti-inflammatory drugs (NSAIDs) are com- monly used to treat postoperative inflammation and pain following cataract surgery and for Cornea and Cataract Service, Florida Eye Microsurgical Institute, Boynton Beach, treatment and prophylaxis of pseudophakic cystoid macular edema (CME). Bromfenac is a FL, USA brominated NSAID with strong in vitro anti-inflammatory potency. Like other ophthalmic NSAIDs, bromfenac is often used outside of the cataract surgery setting. This paper provides an overview of bromfenac’s preclinical ocular pharmacology and pharmacokinetics, followed by a review of 23 published clinical studies in which various marketed bromfenac formula- tions were used for conditions other than cataract surgery or pseudophakic CME. These include: post-refractive eye surgery; macular edema associated with diabetes, uveitis, or fl For personal use only. retinal vein occlusion; in ammation associated with age-related macular degeneration; pain related to intravitreal injections; and other ocular anterior segment and surface disorders with an inflammatory component. The published evidence reviewed supports the safety and effectiveness of bromfenac in these additional ophthalmic indications. Bromfenac was well tolerated when given alone or in combination with intravitreal anti-vascular endothelial growth factor agents, topical corticosteroids, or topical mast-cell stabilizers. The most common adverse event reported was ocular irritation. No serious adverse events (ie, corneal epithelial disorders) were reported, although the majority of studies did not systematically evaluate potential side effects.
    [Show full text]